Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-03-31
2008-09-23
Schnizer, Richard (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S024500, C514S058000
Reexamination Certificate
active
07427605
ABSTRACT:
The present application relates to inhibitors of ribonucleotide reductase subunit 2 (R2), and methods and compositions related to the R2 inhibitors. In certain embodiments, the R2 inhibitors include nucleic acids, such as for example siRNAs.
REFERENCES:
patent: 4945195 (1990-07-01), Ipcinski
patent: 5998383 (1999-12-01), Wright et al.
patent: 6030942 (2000-02-01), Cooperman et al.
patent: 7056704 (2006-06-01), Tuschl et al.
patent: 7098030 (2006-08-01), Rozema et al.
patent: WO02/24864 (2002-03-01), None
Cerqueria et al., 2005, Overview of ribonucleotide reductase inhibitors: an appealing target in anti-tumour therapy, Curr. Med. Chem. 12:1283.
Database EMBL, Aug. 12, 2002, XP0024007222, database accession No. BQ670934.
Duxbury et al., 2004, Retrovirally mediated RNA interference targeting the M2 subunit of ribonucleotide reductase: A novel therapeutic strategy in pancreatic cancer, Surgery 136:261-269.
Duxbury et al., 2004, RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine, Oncogene 28:1539-1548.
Kim et al., 2002, Database EMBL, XP002407223, Database accession No. BM754277.
Kittler et al., 2004, An endoribonuclease-prepared siRNA screen in human cells identifies genes essential for cell division, Nature 432:1036-1040.
Lin et al., 2004, Stable suppression of the R2 subunit of ribonucleotide reductase by R2-targeted short interference RNA sensitizes p53(-/-) HCT-116 colon cancer cells to DNA-damaging agents and ribonucleotide reductase inhibitors, J. Biol. Chem. 279:27030.
Zhou et al., 2003, The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53, Cancer Res. 63:6583-6594.
Davis Mark E.
Heidel Jeremy D.
Rossi John J.
Calando Pharmaceuticals, Inc.
Ropes & Gray LLP
Schnizer Richard
LandOfFree
Inhibitors of ribonucleotide reductase subunit 2 and uses... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of ribonucleotide reductase subunit 2 and uses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of ribonucleotide reductase subunit 2 and uses... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3990766